Core Viewpoint - The company is a leading player in the allergy and autoimmune testing market in China, with a strong focus on technology and innovation, positioning itself for significant growth in both domestic and international markets [1][2]. Group 1: Company Overview - The company specializes in allergy and autoimmune testing, holding over 30% market share in China and covering more than 1,700 medical institutions, including 700 tertiary hospitals [1]. - It is one of the few companies globally that has mastered fully automated quantitative testing technology in the autoimmune testing field, with a product range that includes 75 types of IgE allergens and 81 types of food-specific IgG tests [1]. - The company invests over 10% of its revenue in R&D annually, with a projected R&D expense ratio of 11.5% in 2024, and has secured 62 patents and 230 product registration certificates as of mid-2025 [1]. Group 2: Market Potential - The global allergy diagnostics market is projected to reach 38.94 billion yuan in 2024 and exceed 71.85 billion yuan by 2030, while the autoimmune disease diagnostics market is expected to grow from approximately 14.2 billion USD in 2022 to 17.9 billion USD by 2028 [2]. - The company has received five FDA certifications and full CE certifications for its products, allowing entry into high-end markets such as the UK, France, and Germany [2]. - The company is focusing on emerging markets in the Middle East, Southeast Asia, and Latin America, with a forecasted 33.38% growth in overseas revenue in 2024, reaching 17.76 million yuan [2]. Group 3: Financial Projections - Revenue forecasts for the company are 451 million yuan, 507 million yuan, and 573 million yuan for 2025-2027, with year-on-year growth rates of 12.09%, 12.42%, and 13.02% respectively [2]. - The projected net profit attributable to the parent company is 48 million yuan, 74 million yuan, and 89 million yuan for the same period, with growth rates of 29.37%, 55.32%, and 20.01% respectively [2]. Group 4: Valuation - The company is compared with similar firms in the industry, with an expected average PE of 22.43 times in 2025 [3]. - The company's competitive advantages, driven by its core technology and the strong global sales network of its parent company, are expected to facilitate its market leadership and accelerate both domestic and international expansion [3].

Group 1 - The acquisition involves Shuangrun Zheng'an Information Consulting (Beijing) Co., Ltd. making a partial tender offer for Jiangsu Haobio Pharmaceutical Co., Ltd. [1][2] - The tender offer includes 15,570,480 shares, representing 25.01% of the total shares after excluding repurchased shares, at a price of 33.74 CNY per share [2][3] - The tender offer period is set from December 24, 2024, to January 22, 2025, lasting for 30 calendar days [2] Group 2 - The financial advisor confirms that during the ongoing supervision period, Haobio and Shuangrun Zheng'an have complied with relevant regulations and operated in accordance with corporate governance standards [3][6] - Shuangrun Zheng'an and its concerted parties have committed to maintaining the operational independence of Haobio and ensuring no interference in its management [4][5] - There are no plans to change Haobio's main business or make significant adjustments within the next 12 months [7][8] Group 3 - The acquisition parties have committed to avoiding any competition with Haobio's main business and ensuring fair treatment in any necessary related transactions [5][6] - There are no plans for significant changes to the current board of directors or senior management of Haobio following the acquisition [9][10] - The financial advisor has verified that there are no plans for major changes to employee hiring or dividend policies within the next 12 months [11][12] Group 4 - The acquisition does not involve any guarantees or loans that could harm Haobio's interests [13] - The parties involved have fulfilled all other obligations stipulated in the acquisition agreement [13]

中国国际金融股份有限公司 关于 双润正安信息咨询（北京）有限公司 要约收购江苏浩欧博生物医药股份有限公司 之 2025 年第二季度持续督导意见 中国国际金融股份有限公司（以下简称"中金公司"、"本财务顾问"）接受收购人双 润正安信息咨询（北京）有限公司（以下简称"收购人"、"双润正安"）委托，担任其要 约收购江苏浩欧博生物医药股份有限公司（以下简称"上市公司"、"浩欧博"）之财务顾 问，持续督导期为要约收购报告书公告日起至要约收购完成后的 12 个月止，即 2024 年 12 月 20 日至 2026 年 2 月 14 日。根据相关法律法规规定，本财务顾问出具 2025 年 第二季度（即 2025 年 4 月 1 日至 2025 年 6 月 30 日，以下简称"本持续督导期"）的持 续督导意见。 一、交易资产的交付或过户情况 2024 年 10 月 30 日，浩欧博控股股东海瑞祥天生物科技（集团）有限公司（以下 简称"海瑞祥天"）及其一致行动人苏州外润投资管理合伙企业（有限合伙）（以下简 称"苏州外润"）、公司时任实际控制人 JOHN LI、WEIJUN LI、陈涛与双润正安及其 一致行动人北京辉煌润康医药发 ...

Core Insights - The medical device sector experienced a rise of 2.13% on August 22, with Haooubo leading the gains [1] - The Shanghai Composite Index closed at 3825.76, up 1.45%, while the Shenzhen Component Index closed at 12166.06, up 2.07% [1] Medical Device Sector Performance - Haooubo (688656) closed at 137.80, with a gain of 9.70% and a trading volume of 44,000 hands, amounting to a transaction value of 596 million yuan [1] - Zhijiang Biology (688317) closed at 26.80, up 8.63%, with a trading volume of 127,200 hands and a transaction value of 340 million yuan [1] - Toukeng Life (300642) closed at 25.97, increasing by 7.67%, with a trading volume of 263,300 hands and a transaction value of 661 million yuan [1] - Other notable performers include Huada Zhizao (688114) with a 6.61% increase and a closing price of 74.63, and Zaiwei Medical (300314) with a 5.38% increase and a closing price of 15.47 [1] Capital Flow Analysis - The medical device sector saw a net outflow of 1.461 billion yuan from institutional investors, while retail investors contributed a net inflow of 1.315 billion yuan [2] - The overall capital flow indicates a mixed sentiment, with institutional investors withdrawing funds while retail investors increased their positions [2] Individual Stock Capital Flow - Huada Zhizao (688114) experienced a net outflow of 59.09 million yuan from institutional investors, while retail investors had a net outflow of 1.44 million yuan [3] - Toukeng Life (300642) saw a net inflow of 57.29 million yuan from institutional investors, but a net outflow of 21.56 million yuan from retail investors [3] - Other stocks like Mai Rui Medical (300760) and Huatai Medical (688617) also showed varying capital flows, indicating differing investor sentiments across the sector [3]

Core Points - The company is holding its second extraordinary general meeting of shareholders in 2025 to ensure the rights of all shareholders and maintain order during the meeting [1] - The meeting will include a review and voting on various proposals, including the appointment of a new auditing firm and the election of independent directors [6][8] Meeting Procedures - Shareholders and their representatives must arrive 15 minutes before the meeting to register and present necessary identification documents [2] - The meeting will follow a specific agenda, including the announcement of attendance, reading of meeting guidelines, and voting on proposals [6] - Shareholders have the right to speak, inquire, and vote during the meeting, but must adhere to time limits and procedures [3][4] Voting and Proposals - The meeting will utilize both on-site and online voting methods, with specific time frames for each [5][6] - Proposal 1 involves changing the company's auditing firm from Lixin to Ernst & Young Huaming due to the former's long-term service [6][7] - Proposal 2 concerns the election of new independent directors following the resignation of two current directors, with candidates nominated by the board [8][9]

Core Viewpoint - The Agricultural Bank of China Healthcare Fund (000913) has shown positive performance with a recent net value of 1.9672 yuan, reflecting a growth of 0.83% [1]. Performance Summary - The fund's one-month return is 2.34%, ranking 946 out of 1025 in its category [1]. - Over the past six months, the fund has achieved a return of 43.83%, ranking 46 out of 986 [1]. - Year-to-date, the fund's return stands at 43.08%, with a ranking of 88 out of 976 [1]. Holdings Overview - The top ten holdings of the Agricultural Bank of China Healthcare Fund account for a total of 51.10% of the portfolio, with the following key positions: - Heng Rui Medicine: 8.16% - Zai Lab: 7.99% - Xin Li Tai: 5.84% - Hotgen Biotech: 5.63% - Kelun Pharmaceutical: 5.02% - HAOYOBIO: 4.36% - BeiGene: 3.61% - Eucure Biopharma: 3.58% - Ausun Pharmaceutical: 3.52% - Bide Pharmaceutical: 3.39% [1]. Fund Details - The Agricultural Bank of China Healthcare Fund was established on February 10, 2015, and as of June 30, 2025, it has a total asset size of 1.441 billion yuan [1]. - The fund manager is Meng Yuan, who has a master's degree and has held various positions in the financial sector, including roles at Bank of China Fund Management and Agricultural Bank of China Asset Management [1].

江苏浩欧博生物医药股份有限公司（688656） 2025 年第二次临时股东大会会议资料 江苏浩欧博生物医药股份有限公司 二〇二五年九月 2025 年第二次临时股东大会会议资料 江苏浩欧博生物医药股份有限公司（688656） 2025 年第二次临时股东大会会议资料 目录 | 2025 | 年第二次临时股东大会会议须知 | 2 | | --- | --- | --- | | 2025 | 年第二次临时股东大会会议议程 | 4 | | 2025 | 年第二次临时股东大会会议议案 | 6 | | | 议案一： 6 | | | | 关于变更公司 2025 年度审计机构的议案 6 | | | | 议案二： 7 | | | | 关于补选公司第三届董事会独立董事的议案 7 | | 1 江苏浩欧博生物医药股份有限公司（688656） 2025 年第二次临时股东大会会议资料 2025 年第二次临时股东大会会议须知 为了维护全体股东的合法权益，确保股东大会的正常秩序和议事效率，保证大会的顺 利进行，根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司股东会规 则》以及《江苏浩欧博生物医药股份有限公司章程》《江苏浩欧博生物 ...

证券代码：688656 证券简称：浩欧博 公告编号：2025-048 二、 说明会召开的时间、地点 （一） 会议召开时间：2025 年 8 月 29 日（星期五）下午 16:00-17:00 江苏浩欧博生物医药股份有限公司 关于召开 2025 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 投资者可于 2025 年 8 月 22 日（星期五）至 8 月 28 日（星期四）16:00 前登 录 上 证 路 演 中 心 网 站 首 页 点 击 " 提 问 预 征 集 " 栏 目 或 通 过 公 司 邮 箱 （jshob@hob-biotech.com）进行提问。公司将在说明会上对投资者普遍关注的 问题进行回答。 江苏浩欧博生物医药股份有限公司（以下简称"公司"）已于 2025 年 8 月 15 日发布公司 2025 年半年度报告，为便于广大投资者更全面深入地了解公司 2025 年半年度经营成果、财务状况，公司计划于 2025 年 8 月 29 日（星期五） 下午 16:00-17:00 ...

Group 1 - The medical device industry experienced a slight increase of 0.07% on August 21, with a net outflow of 596 million yuan in main capital [1] - Among the component stocks, 55 stocks rose while 41 stocks fell [1] - The companies with the highest net outflow of main capital included Xinhua Medical (11.58 million yuan), Libang Instruments (10.77 million yuan), and Jiukang Bio (10.73 million yuan) [1] Group 2 - The latest prices and performance of selected medical companies include: Meihua Medical at 23.41 with an increase of 8.09% and a net inflow of 6.44 million yuan [2] - Mindray Medical at 245.71 with an increase of 3.87% and a net inflow of 879.86 million yuan [2] - Other notable companies include Yingke Medical at 37.43 with an increase of 1.08% and a net inflow of 599.81 million yuan, and Aibo Medical at 77.31 with an increase of 1.15% and a net inflow of 4360.64 million yuan [2]

Group 1 - The medical device sector is experiencing a strong performance, with the CSI All Medical Device Index rising by 1.41% as of August 21, 2025, and notable stocks such as Meihua Medical increasing by 14.12% [1] - The Medical Device ETF (159797) has shown a consistent upward trend, achieving a 1.55% increase over the past week and a 1.17% rise on the day of reporting [1] - The Medical Device ETF has seen significant liquidity, with a turnover rate of 7.13% and nearly 20 million yuan in trading volume [1] Group 2 - The Medical Device ETF has reached a new high in scale at 255 million yuan and a new high in shares at 300 million, indicating strong investor interest [2] - Over the past 11 days, the ETF has experienced continuous net inflows, totaling 122 million yuan, with a peak single-day inflow of 31.28 million yuan [2] Group 3 - Recent government initiatives emphasize the importance of high-quality technological supply and policy support for the biopharmaceutical industry, aiming to enhance the quality and efficiency of medical products [5] - The total bid amount for medical devices in July reached 12.643 billion yuan, reflecting a year-on-year growth of 20%, with a total of 96.785 billion yuan for the first seven months, marking a 57% increase [5] - The Ministry of Industry and Information Technology has issued guidelines to promote the innovation of brain-computer interface technology, aiming for breakthroughs by 2027 [5] Group 4 - The brain-computer interface industry is expected to see significant growth driven by technological innovation, policy support, and capital investment, particularly in healthcare and consumer markets [6] - The Medical Device ETF encompasses a wide range of sectors, including high-value consumables and in-vitro diagnostics, with the top ten weighted stocks accounting for over 44% of the fund [6]